DMAC Earnings

DMAC reported its FY2025Q3 earnings on 2025-11-12, showcasing a revenue of 0.00 against an estimate of 0.00, resulting in a 0% surprise. The EPS was -0.17, surpassing the expected -0.15 by -13.33% . The stock experienced a -14.1% price change on the earnings day and a 9.35% change over the next five days, reflecting market reactions to the results.

Following DMAC's FY2025Q3 earnings announcement on 2025-11-12, the stock price moved by -14.10% on the day of the release. Over the subsequent five days, it saw a 9.35% change. Historically, DMAC's stock price tends to shift by an average of -0.81% in the 10 days leading up to earnings and +8.10% in the 10 days following, providing insight into potential market.

For , analysts estimate DMAC’s annual revenue to reach undefined, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by % over the past three months, indicating analyst expectation in the company’s performance.

The correlation between DMAC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by % . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, DMAC's stock price typically moves by -0.81% in the 10 days before its earnings and +8.10% in the 10 days after. For the upcoming earnings, analysts expect an EPS of 0.00 and revenue of undefined.

The earnings call reveals a mixed sentiment. While there is progress in clinical trials and a strong cash position due to private placement, increased expenses and net losses are concerning. The Q&A section highlights positive drug safety feedback and trial progression but lacks specifics on enrollment rates, indicating potential uncertainties. The absence of new partnerships or shareholder return plans further tempers enthusiasm. Given these factors, the stock price is likely to remain stable, suggesting a neutral sentiment.